GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Equity-to-Asset

Sino Biopharmaceutical (FRA:SMZ1) Equity-to-Asset : 0.46 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sino Biopharmaceutical's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €3,865 Mil. Sino Biopharmaceutical's Total Assets for the quarter that ended in Jun. 2023 was €8,460 Mil. Therefore, Sino Biopharmaceutical's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was 0.46.

The historical rank and industry rank for Sino Biopharmaceutical's Equity-to-Asset or its related term are showing as below:

FRA:SMZ1' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36   Med: 0.46   Max: 0.58
Current: 0.48

During the past 13 years, the highest Equity to Asset Ratio of Sino Biopharmaceutical was 0.58. The lowest was 0.36. And the median was 0.46.

FRA:SMZ1's Equity-to-Asset is ranked worse than
65.62% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs FRA:SMZ1: 0.48

Sino Biopharmaceutical Equity-to-Asset Historical Data

The historical data trend for Sino Biopharmaceutical's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Equity-to-Asset Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 0.36 0.50 0.46 0.48

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.47 0.46 0.46 0.48

Competitive Comparison of Sino Biopharmaceutical's Equity-to-Asset

For the Biotechnology subindustry, Sino Biopharmaceutical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Equity-to-Asset falls into.



Sino Biopharmaceutical Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sino Biopharmaceutical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=4027.884/8674.596
=0.46

Sino Biopharmaceutical's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )=Total Stockholders Equity/Total Assets
=3865.183/8460.153
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (FRA:SMZ1) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Sino Biopharmaceutical Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (FRA:SMZ1) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (FRA:SMZ1) Headlines

No Headlines